Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB StudyValentina Guarneri, PierFranco Conte, Samanta Sarti et al.|Journal of Clinical Oncology|2012Cited by 368
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).Valentina Guarneri, PierFranco Conte, Antonio Frassoldati et al.|Journal of Clinical Oncology|2011Cited by 32